Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 5/22/2008 First Published: 2/22/2008


1.		Phase I/II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following Chemoimmunotherapy Comprising Rituximab, Fludarabine, and Cyclophosphamide in Patients With CD20-Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UMN-2007LS064 UMN-2007LS064, MT2007-12, UMN-0707M13561, NCT00625729

Last Modified: 5/6/2008 First Published: 4/2/2008


2.		Phase II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following a Preparative Regimen Comprising Cyclophosphamide and Fludarabine Phosphate in Patients With Recurrent and/or Metastatic Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				UMN-2007LS138 UMN-2007LS138, UMN-MT2007-19R, UMN-WCC-53, UMN-0712M23462, NCT00652899

First Published: 12/23/2008


3.		Phase II Randomized Study of Intralesional Lymphokine-Activated Killer Cells Versus Polifeprosan 20 With Carmustine Implant (Gliadel® Wafer) as Consolidation Therapy After Primary Therapy in Patients With Newly Diagnosed Resectable Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				HOAG-HCC-08-01 HCC 08-01, NCT00814593


4.		Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				UARK 2003-18 NCT00089453

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute